Contrasting Positron (OTCMKTS:POSC) and AngioDynamics (NASDAQ:ANGO)

Positron (OTCMKTS:POSC) and AngioDynamics (NASDAQ:ANGO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Earnings and Valuation

This table compares Positron and AngioDynamics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Positron	$590,000.00	116.92	-$2.39 million	($0.12)	-17.50
AngioDynamics	$292.50 million	1.55	-$33.99 million	($0.67)	-16.40

Positron has higher earnings, but lower revenue than AngioDynamics. Positron is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Positron and AngioDynamics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Positron	N/A	-311.50%	-89.54%
AngioDynamics	-9.02%	-2.28%	-1.50%

Insider and Institutional Ownership

89.4% of AngioDynamics shares are owned by institutional investors. 17.2% of Positron shares are owned by insiders. Comparatively, 6.0% of AngioDynamics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Positron has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, AngioDynamics has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Positron and AngioDynamics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Positron	0	0	0	0	0.00
AngioDynamics	1	0	3	1	2.80

AngioDynamics has a consensus target price of $19.33, suggesting a potential upside of 75.92%. Given AngioDynamics’ stronger consensus rating and higher probable upside, analysts plainly believe AngioDynamics is more favorable than Positron.

Summary

AngioDynamics beats Positron on 9 of the 15 factors compared between the two stocks.

About Positron

Positron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.

About AngioDynamics

AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.